Bristol Myers Squibb stock: BMS joins Erasca cancer trial
Published on 11/18/2026 at 12:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTrial expands oncology pipeline
- Bristol Myers Squibb will sponsor a Phase 1/2 study combining navlimetostat with Erasca's ERAS-0015.
- Erasca will supply its investigational pan-RAS molecular glue, while both companies retain rights to their own compounds.
- The program targets MTAP-deleted pancreatic ductal adenocarcinoma, where concurrent RAS and PRMT5 inhibition may offer a scientific rationale.
On November 17, 2026, Erasca announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb to test ERAS-0015 in combination with navlimetostat, BMS's investigational PRMT5 inhibitor. Bristol Myers Squibb will sponsor the Phase 1/2 study, while Erasca will provide ERAS-0015.
Bristol Myers Squibb stock traded at 57.43 euros on Lang & Schwarz at 12:40 CET on Wednesday, November 18, 2026.
Combination targets pancreatic cancer
The planned study will evaluate the combination in patients with MTAP-deleted pancreatic ductal adenocarcinoma. Erasca said the parties will retain development and commercial rights to their respective compounds, and described the agreement as mutually non-exclusive.
The scientific rationale rests on the biology of the targeted tumors. Erasca said nearly all MTAP-deleted pancreatic cancers carry co-occurring RAS mutations. That combination may create a dependency on pathways affected by simultaneous RAS and PRMT5 inhibition, potentially allowing the two investigational medicines to be studied together in a setting with significant treatment needs.
ERAS-0015 is an oral pan-RAS molecular glue designed to inhibit RAS signaling. Erasca is evaluating the compound in its AURORAS-1 Phase 1 study in patients with RAS-mutant solid tumors. The company said early dose-escalation data showed favorable safety and tolerability, linear pharmacokinetics and confirmed or unconfirmed partial responses across several tumor types and RAS mutations. Those observations remain part of an early-stage development program rather than evidence of regulatory approval or commercial availability.
Strategic relevance for BMS
For Bristol Myers Squibb, the collaboration adds an external precision-oncology asset to a pipeline that includes both marketed medicines and investigational programs. The proposed combination pairs a RAS-directed approach with a BMS PRMT5 inhibitor, giving the company a way to test complementary mechanisms in pancreatic cancer without acquiring Erasca or taking ownership of ERAS-0015.
Erasca's management said the partnership is intended to explore whether ERAS-0015 can serve as a combination backbone across RAS-mutant cancers. The company also said the combination could increase potential patient benefit, but the release cautioned that development timing, trial outcomes and therapeutic benefits remain subject to clinical and regulatory risks.
The next material step is the conduct of the planned Phase 1/2 evaluation. The announcement did not provide a study readout date, a financial payment, or a commercial launch timetable. Investors will therefore focus on trial initiation, enrollment and future clinical data as the program develops.
The broader US market can be followed through the S&P 500.
More news and analyses on Bristol Myers Squibb stock.
Bristol Myers Squibb at a glance
- Company: Bristol-Myers Squibb Company
- ISIN: US1101221083
- WKN: 850501
- NYSE ticker: BMY
- Lang & Schwarz quote: 57.43 euros at 12:40 CET on November 18, 2026
- Sector: Healthcare
- Industry: Drug Manufacturers - General
